PT  - JOURNAL ARTICLE
AU  - Oh, Jiwon
AU  - O’Connor, Paul W.
TI  - Teriflunomide
AID  - 10.1212/CPJ.0b013e318296f299
DP  - 2013 Jun 01
TA  - Neurology: Clinical Practice
PG  - 254--260
VI  - 3
IP  - 3
4099  - http://cp.neurology.org/content/3/3/254.short
4100  - http://cp.neurology.org/content/3/3/254.full
AB  - Teriflunomide is a novel disease-modifying agent that was recently approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration. Furthermore, existing clinical experience with its parent drug, leflunomide, provides indirect long-term safety data. This review summarizes teriflunomide's pharmacologic properties, pivotal clinical trials, and safety profile, and ends with a discussion of the role of teriflunomide in the context of current and emerging MS treatment options.